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A B S T R A C T
Exposure to selenium, and particularly to its inorganic forms, has been hypothesized as a risk factor for
amyotrophic lateral sclerosis (ALS), a fast progressing motor neuron disease with poorly understood
etiology. However, no information is known about levels of inorganic and some organic selenium species
in the central nervous system of ALS patients, and recent observations suggest that peripheral
biomarkers of exposure are unable to predict these levels for several Se species including the inorganic
forms. Using a hospital-referred case–control series and advanced selenium speciation methods, we
compared the chemical species of selenium in cerebrospinal ﬂuid from 38 ALS patients to those of 38
reference neurological patients matched on age and gender. We found that higher concentrations of
inorganic selenium in the form of selenite and of human serum albumin-bound selenium were
associated with increased ALS risk (relative risks 3.9 (95% conﬁdence interval 1.2–11.0) and 1.7 (1.0–2.9)
for 0.1 mg/L increase). Conversely, lower concentrations of selenoprotein P-bound selenium were
associated with increased risk (relative risk 0.2 for 1 mg/L increase, 95% conﬁdence interval 0.04–0.8).
The associations were stronger among cases age 50 years or older, who are postulated to have lower rates
of genetic disease origin. These results suggest that excess selenite and human serum albumin bound-
selenium and low levels of selenoprotein P-bound selenium in the central nervous system, which may be
related, may play a role in ALS etiology.
 2013 The Authors. Published by Elsevier Inc. 
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Selenium (Se), an essential trace mineral, has both nutritional
and toxicological properties, with a broad range of biological
activities which strongly depend on its chemical form. Inorganic
species of Se are generally more toxic and of lower nutritional
value than the organic species (Vinceti et al., 2009; Valdiglesias
et al., 2010; Nogueira and Rocha, 2011), in some cases exhibiting* Corresponding author at: CREAGEN – Dipartimento di Medicina Clinica,
Diagnostica e di Sanita` Pubblica, Universita` di Modena e Reggio Emilia, Via Campi
287, 41125 Modena, Italy. Tel.: +39 059 2055 481; fax: +39 059 2055 483.
E-mail address: marco.vinceti@unimore.it (M. Vinceti).
0161-813X       2013 The Authors. Published by Elsevier Inc. 
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Open access under CC BY-NC-Nentirely different effects (Borella et al., 1996; Hoeﬁg et al., 2011;
Nogueira and Rocha, 2011; Bodnar et al., 2012; Bitencourt et al., in
press), and more generally, each Se compound has speciﬁc and
distinctive biological properties. Unfortunately, most human
studies have investigated the overall Se content of body tissues
without assessing the different chemical species of the metalloid.
Moreover, the levels of Se and of speciﬁc Se compounds in the
different body tissues may considerably vary and are frequently
uncorrelated, hampering or even precluding assessment of their
concentrations in target organs and compartments of relevance for
speciﬁc diseases on the basis of peripheral indicators of exposure
(such as blood or toenails Se) or dietary intake of the metalloid
(Behne et al., 2010; Dennert et al., 2011; Vinceti et al., 2012b). This
may be particularly true when attempting to assess involvement of
Se species in the etiology of human neurological diseases: a recent
Se speciation studies has found that while peripheral (blood) levels
of some organic Se compounds tend to reﬂect central nervousD license.
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species such as selenoprotein P, overall Se content and the
inorganic forms selenate and selenite (Solovyev et al., 2013),
conﬁrming previous observations on overall Se (Michalke et al.,
2009). Other observations appear to conﬁrm the independence of
brain selenoprotein P compared with its plasma circulating levels
(Scharpf et al., 2007).
Amyotrophic lateral sclerosis (ALS), a severe degenerative
motor neuron disease of largely unknown etiology apart from the
few cases of genetic origin, is among the diseases whose etiology is
hypothesized to be related to overexposure to selenium (Vinceti
et al., 2012a). This hypothesis was ﬁrst proposed based on
observation of a cluster of ALS cases in a seleniferous area of South
Dakota, and an excess incidence of ALS in an Italian population
consuming drinking water with high concentrations of the
inorganic Se species selenate (Kilness and Hochberg, 1977; Vinceti
et al., 1996, 2010b). Consistent with the hypothesis is the
demonstration of Se-induced neurotoxicity in laboratory studies
(Ammar and Couri, 1981; Nogueira et al., 2003; Maraldi et al.,
2011; Estevez et al., 2012) and its selective toxicity on motor
neurons in species such as swine (Casteignau et al., 2006; Raber
et al., 2010; Vinceti et al., 2012a), generally showing a much higher
or even an exclusive toxicity of inorganic species compared with
the organic ones. Moreover, recent epidemiologic observations
suggest deleterious effect of Se on neurological end-points such as
visual evoked potentials (Saint-Amour et al., 2006) and, even at low
doses of exposure, neonatal neurological and behavioral develop-
ment (Yang et al., 2013).
We conducted a case–control study to examine the hypothesis
that Se species and particularly the inorganic ones are associated
with ALS risk by using a CNS biomarker of exposure, cerebrospinal
ﬂuid (CSF), which appears to play a key role in assessing exposure
to etiopathogenetic and therapeutic factors in this disease
(Tarasiuk et al., 2012; von Neuhoff et al., 2012; Wilson et al.,
2013; Winer et al., 2013).
2. Methods
2.1. Study participants
ALS patients were recruited from a case series of residents of the
Emilia-Romagna region, northern Italy, who were diagnosed with
clinically deﬁnite or clinically probable ALS using the revised El
Escorial Criteria (Georgoulopoulou et al., 2011) at the ALS Center of
the Modena University Neurological Department from May 1998
to April 2011, and who underwent lumbar puncture during
diagnostic procedures. This group comprised 72 consecutive
patients with sporadic ALS, some of whom were enrolled in a
previous study (Mandrioli et al., 2006). Thirty-eight patients had at
least 1 mL CSF available when the present study was designed and
composed the enrolled cases. We recently performed genetic
screening including all the major genes that are implicated in ALS
(SOD1, C9ORF72, FUS, TDP43) in 12 of these patients, generally the
younger ones, with none testing positive. We were not allowed to
perform genetic analysis in the remaining patients because of lack
of informed consent and/or available blood samples.
The control population consisted of patients residing in the
Emilia-Romagna region who were admitted to the same depart-
ment between 1999 and 2010, inclusive, and underwent lumbar
puncture because of suspected but later unconﬁrmed neurological
disease, and had a sample of at least 1 mL of CSF still available in
September 2011. Among these individuals, we randomly selected
38 subjects matched 1:1 to ALS cases on age (10 years, in most
cases 5 years) and gender. Signs or symptoms that led to
neurological examination and lumbar puncture were: headache
(n = 17), paresthesias (n = 5), diplopia (n = 6), vertigo (n = 3) and other(n = 7). All control patients were subsequently discharged from
hospital without a diagnosis of a major disease; ﬁnal diagnosis was
primary headache in 13 individuals, and other diagnoses with
negative instrumental tests in the remaining 25 individuals.
Informed consent for diagnostic lumbar puncture was obtained
from all patients, and utilization of the CSF specimens for the
present study was approved by the Modena Ethical Committee.
2.2. Sample collection
Approximately 6 mL of CSF were collected by lumbar puncture
from each patient and immediately stored at 80 8C in polypro-
pylene tubes. A 1 mL aliquot was transported by air courier deep
frozen in dry ice to the Munich laboratory, and kept continuously
frozen until use. For analysis, samples were slowly thawed in a
refrigerator at 4 8C, vortexed and subsequently analyzed.
2.3. Chemicals
Suprapure grade chemicals were used throughout. Selenite,
selenate, selenomethionine (Se-Met), selenocystine (Se-Cys),
thioredoxin reductase (EC 1.8.1.9.)-bound selenium (Se-TrxR),
glutathione peroxidase (EC 232-749-6)-bound selenium (Se-GPx),
human serum albumin (HSA) and Tris buffer were ordered from
Sigma–Aldrich, Deisenhofen, Germany. Certiﬁed Se and Rh stock
standards (1000 mg/L) were purchased from CPI International,
Santa Rosa, CA, USA. Ammonium acetate (NH4Ac) and acetic acid
(HAc) were obtained from Merck, Darmstadt, Germany. Arliq and
methane (99.999% purity) were purchased from Air Liquide,
Gro¨benzell, Germany. Selenite and selenate stock solutions were
prepared at a concentration of 1000 mg Se/L by dissolving in Milli-
Q water (18.2 MV cm, Milli-Q system, Millipore, Bedford, MA,
USA). HSA was prepared at a concentration of 1000 mg/L.
Preparation of Se-HSA was performed by mixing 10 mg Se/L
selenite with this stock solution and incubating for at least 14 days.
Working standards of Se species were prepared daily from their
stock standard solutions by appropriate dilution with Milli-Q H2O.
Selenoprotein P-bound Se (SePP) is not commercially available as a
standard compound, but it can be prepared from serum using
afﬁnity chromatography (AFC): The AFC-SePP fraction was puriﬁed
by a mass-calibrated size exclusion chromatography (SEC) column,
where the SePP fraction eluted at a RT calculated for 61.8 kDa.
2.4. Selenium speciation
We determined total Se and the Se species selenite, selenate, Se-
Met, Se-Cys, Se-TrxR, Se-GPx, SePP and Se-HSA in the CSF samples
using high pressure liquid chromatography (HPLC) coupled with
inductively coupled plasma dynamic reaction cell mass spectrom-
etry (ICP-DRC-MS) according to methodologies previously estab-
lished for biological matrices, speciﬁcally for CSF (Michalke and
Berthele, 2011; Solovyev et al., 2013). Se speciation was conducted
by strong anion exchange (SAX)-ICP-DRC-MS (Michalke and
Berthele, 2011). The SAX separation followed Xu et al. (2008)
but was slightly modiﬁed for baseline separation of close eluting
peaks.
A Knauer 1100 Smartline inert Series gradient HPLC system was
connected to an anion exchange column ProPac SAX-10
(250  2 mm I.D.) from Thermo (Dionex Idstein, Germany) for
species separation. The sample volume was 100 ml. The mobile
phases were: eluent A: 10 mM Tris–HAc, pH 8.0; and eluent B:
A + 500 mM NH4Ac, pH 8.0. Gradient elution expressed as %-eluent
A: 0–3 min 100%; 3–10 min 100–60%; 10–23 min 60–45%; 23–
26 min 45–43%; 26–28 min 43–0%; 28–52 min 0%; 52–60 min
100%. The ﬂow rate was 0.20 mL min1. For internal standardiza-
tion the column efﬂuent was mixed with 1 mg/L Rh (ﬁnal
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ICP–MS.
Total Se was analyzed by ﬂow injection (FI)-ICP-DRC-MS
(Michalke et al., 2009). A Knauer 1100 Smartline inert Series
HPLC system equipped with vacuum degasser and an electronic
valve with a 25 ml injection loop (Perkin Elmer, Rodgau-Ju¨gesheim,
Germany) was directly coupled to ICP-DRC-MS. The ﬂow rate was
1 mL min1 of 50% eluents A and B, each, from SAX separation. CSF-
samples were diluted 1:1.1 by adding 1 mg/L Rh (ﬁnal conc.) as
internal standard.
The experimental settings chosen for ICP-DRC-MS (Perkin
Elmer NexIon) after optimization were: radio frequency power:
1250 W, plasma gas ﬂow: 15 L Ar/min auxiliary gas ﬂow: 1.05 L
Ar/min, nebulizer gas ﬂow: 0.98 L Ar/min, daily optimized, dwell
time 300 ms, ions monitored: 78Se, 80Se, 103Rh, DRC reaction gas:
CH4 reaction at 0.58 mL min
1, DRC rejection parameter q: 0.6.
Peak quantiﬁcation from FI-quantiﬁcation and from chromato-
grams was done by comparing peak areas with peak area
calibration curves from FI-ICP-DRC-MS. Standard addition method
was used for standard-retention-time matched identiﬁcation of Se
species and as QC means in quantiﬁcation. Species identity was
further conﬁrmed using a 2D approach of SAX-capillary electro-
phoresis (CE)-ICP-DRC-MS: SAX fractions were analyzed with CE-
ICP-DRC-MS. In both serially applied separation techniques (SAX,
CE) the observed peaks matched retention- or migration times of
respective standard compounds, in accordance to a parallel
investigation (Solovyev et al., 2013). Species identiﬁcation was
regarded as acceptable when species matched the standard
compounds with both chromatography/electrophoretic techni-
ques (match in ﬁrst and second technique). Details of these
procedures have been published elsewhere (Solovyev et al., 2013).
Rh and Se data ﬁles were exported from the NexIon software and
processed with PeakﬁtTM software for peak area integration. For
each sample (or standard) a quotient of Se-peak area to Rh-peak
area was calculated and taken as the result corrected for the
internal standard (Rh).
In these analyses, in addition to well-known Se organic and
inorganic species, we detected 13 peaks attributable to extremely
small amounts of Se of unknown form; these were added to known
inorganic and organic species to compute total Se. No detectable
trace of Se-Cys was found in any sample. Limit of detection for all
Se species in CSF was 0.01 mg/L, lower than that we obtained in a
recent pilot study in neurologically healthy German individuals
(Solovyev et al., 2013).
2.5. Quality control
For total Se determination, quality control was performed by
analyzing the control materials ‘‘human serum’’ and ‘‘urine’’ from
RECIPE, Munich, Germany. Control materials were reconstituted
as indicated on ﬂask labels and the resulting solutions were
diluted 1/50 (serum) or 1/10 (urine) with Milli-Q water before
measurements. Se concentrations were found to be 62  3 mg/L
(serum, n = 3) and 24  3 mg/L (urine, n = 3), compared to manu-
facturer’s target mean values of 62 and 23 (range: 16–30) mg/L,
respectively.
In a preceding inter-laboratory comparison our SePP quanti-
ﬁcation was compared to the immuno assay method for SePP
determination by Hollenbach et al. (2008). There the reliability
of our SePP determination was veriﬁed: The immunologically
determined SePP concentration in a pooled CSF sample prepared
for the inter-laboratory comparison was 0.54 nM/L (9.5%)
SePP (expressed as total protein). According to literature data
regarding SePP (10 Se atoms per SePP and molecular weight
MW(SePP) = 61 kDa (Ballihaut et al., 2012)) this SePP-protein
concentration refers to 0.43  0.04 mg Se/L at SePP. This valuecorresponded well to the SAX-ICP-DRC-MS value from our method
at 0.41  0.01 mg Se/L at SePP peak: Thus our method was veriﬁed
by an independent reference method.
Besides, the good concordance of our Se species concentrations
in CSF and serum from this and previous papers with some
available Se-species concentrations in literature underlines further
that Se species determinations with our method are at least overall
OK. This is the more important as with the same method cases and
controls were measured and the differences between both are the
relevant issue in this paper.
For recovery determination during SAX-ICP-DRC-MS single Se
species (10 mg Se/L) were analyzed and peak Se concentrations
were quantiﬁed and related to the injected Se amounts (=100%).
Analogously, CSF samples were quantiﬁed for total Se (=100%)
before injection and compared to the sum of eluted and quantiﬁed
chromatographic peaks. Recoveries were 95  9% for CSF, 106 
10% for GPx, 97  8% for selenite, 102  8% for TrxR, 89  8% for Se-
HSA, and 84  13% for SePP, the latter lower recovery being explained
by stability problems accompanied by an increasing selenate signal,
as expected (Michalke and Berthele, 2011).
2.6. Statistical analysis
Analyses were conducted for each Se species and for total
inorganic Se (sum of selenite and selenate), total organic Se (sum of
SePP, Se-GPx, Se-TrxR, Se-Met and Se-HSA), and total Se (sum of
inorganic, organic and unknown forms). Inclusion of Se-HSA in the
organic category was based on the presumption that nearly all of
this Se was organic, most likely in the form of Se-Met (Xu et al.,
2008), though trace amounts of inorganic Se in this compound
cannot be entirely excluded (Haratake et al., 2008).
We tested differences in distribution of Se species in cases and
controls using the Wilcoxon signed-rank test. We estimated the
relative risk (RR) of ALS, as expressed by the odds ratio, associated
with a one-unit increase in single Se species or categories using
conditional logistic regression models. Some Se species distribu-
tions had outliers at high values, which was a concern as they could
act as high leverage points and be unduly inﬂuential in regression
models, especially given the small sample size. We used two
approaches to address such outliers: (1) diagnostics were
conducted to identify highly inﬂuential observations, assessed
by delta beta statistics (Hosmer and Lemeshow, 2000) and
observations with high inﬂuence statistics (delta beta > 0.1) were
omitted and the model was reﬁt and (2) the models were ﬁt using
Se species concentration values that were winsorized by setting
data exceeding the 95th percentile to the 95th percentile. Both sets
of results are presented. Analyses were repeated in the subgroup of
matched pairs in which the case was diagnosed at age 50 or older.
Sensitivity analyses were conducted by selectively omitting from
analyses control patients with speciﬁc symptoms and signs leading
to neurological examination (speciﬁcally, the 17 subjects suffering
from headache, the 5 with paresthesias and the 6 with diplopia).
3. Results
The 38 ALS cases included 16 men and 22 women, with mean
age of 55.5 years (range 30.7–76.4 years), who underwent lumbar
puncture during their diagnostic process for neurological signs and
symptoms of uncertain origin. Seven of these patients were later
diagnosed as having ALS with bulbar onset and 31 as having spinal
onset of the disease, in all cases at a very early clinical stage. The 38
age- and gender-matched controls had mean age 52.6 years (range
30.2–85.5 years).
Table 1 summarizes the distribution of the inorganic and
organic Se species we determined. Of the inorganic forms, selenite
– but not selenate – levels were shifted toward higher values in
Table 1
Distribution of Se species (mg/L) in newly diagnosed amyotrophic lateral sclerosis
cases (n = 38) and controls (n = 38).
Se species Percentile
5th 50th 95th
Selenite
Controls 0 0.026 0.180
Cases 0 0.051 0.169
Selenate
Controls 0 0 0.089
Cases 0 0 0.089
Selenomethioninea
Controls 0 0 0.305
Cases 0 0 0
Thioredoxin reductase-bound Se
Controls 0 0.050 0.389
Cases 0 0.043 0.214
Glutathione peroxidase-bound Se
Controls 0 0.021 0.164
Cases 0 0.026 0.120
Human serum albumin-bound Se
Controls 0 0.087 0.258
Cases 0 0.127 0.359
Selenoprotein P-bound Se
Controls 0.036 0.856 8.121
Cases 0.093 0.577 2.196
Total inorganic Se
Controls 0 0.034 0.180
Cases 0 0.059 0.277
Total organic Se
Controls 0.053 1.084 8.284
Cases 0.287 0.765 2.508
Total Seb
Controls 0.140 1.100 8.380
Cases 0.320 0.765 2.660
a Only four nonzero values of this compound detected.
b Sum of total inorganic and total organic Se and unknown forms.
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lower among cases than among controls, and this was particularly
true for SePP. Overall, levels of organic Se compounds were higher
than levels of inorganic compounds; as a result, total Se was lower
among cases than among controls. Since only four subjects had
detectable Se-Met levels, this species was not analyzed separatelyTable 2
Relative risks (RR) of amyotrophic lateral sclerosis associated with 1 mg/La increase in ce
extremely high inﬂuence statistics.b
Se species All subjects (38 cases, 38 controls) 
RR (95% CI) P-value #Ca
Selenite 3.9 (1.2–11.0) .02 36/
Selenate 0.9 (0.2–4.2) .93 38/
Thioredoxin reductase-bound Se 1.0 (0.9–1.1) .13 37/
Glutathione peroxidase-bound Se 1.0 (0.9–1.1) .47 38/
Human serum albumin-bound Se 1.7 (1.0–2.9) .05 37/
Selenoprotein P-bound Se 0.2 (0.04–0.8) .03 37/
Total inorganic Se
Crude 1.7 (0.8–3.5) .18 36/
Adjusted for organic Se 1.9 (0.8–4.8) .17 36/
Total organic Se
Crude 0.3 (0.1–1.0) .04 36/
Adjusted for inorganic Se 0.3 (0.1–0.9) .04 36/
Total Se 0.3 (0.1–0.9) .03 37/
a Unit increase is 0.1 mg/L for selenate, selenite, total inorganic Se and human serum
b Results obtained from conditional logistic regression models. To reduce the inﬂue
unusually high inﬂuence statistics (delta beta > 0.1) were omitted, resulting in smallerin subsequent analyses. Median values in controls were roughly
comparable to CSF Se species levels recently detected in a series of
24 patients with unspeciﬁc neurological complaints from the
Department of Neurology of the Technical University Munich
(Solovyev et al., 2013), which reported median levels of total
Se = 0.861, SePP = 0.474, Se-GPx = 0.036, Se-TrxR = 0.035, Se-
HSA = 0.068, selenite = 0.046, and selenate lower than the detec-
tion limit (all concentrations expressed as mg/L).
In conditional logistic regression models omitting gross outliers
from analysis, the relative risk (RR) of ALS increased with
increasing selenite content of CSF but not selenate content
(Table 2). The RR increased with increasing Se-HSA concentration
and decreased with increasing SePP concentration. The RR
similarly decreased with increasing total organic Se, both
unadjusted and adjusted for inorganic Se, and with increasing
total Se. In analyses restricted to case–control pairs in which the
case was diagnosed at age 50 or older, associations were generally
stronger. All patients omitted as outliers had delta beta statistics
(indicating the change in the beta coefﬁcient when the observation
is omitted) that were grossly large compared to those for other
observations (for example, delta betas of 0.13 and 0.45 for selenite,
whereas the other 74 observations had values between 0 and
0.036), and were above the 95th percentile of their Se species
distributions. Comparing included subjects to patients excluded as
outliers, median time from onset to lumbar puncture was 15 vs. 13
months, respectively, and median survival after diagnosis was 44
vs. 45 months, respectively.
Results were similar when conducting the analyses using
winsorized distributions of the Se species (Table 3), but with
estimates generally closer to the null value, with the exception of
analyses for total inorganic Se among the older age at diagnosis
subsample, which showed stronger associations in the winsorized
analysis.
In sensitivity analyses selectively omitting subgroups of control
subjects with speciﬁc neurological symptoms and signs, no
substantially different results emerged.
4. Discussion
Overall Se content in body tissues such as blood, nails, brain and
spinal cord of ALS patients has previously been investigated
(Mitchell et al., 1991; Moriwaka et al., 1993; Ince et al., 1994;
Bergomi et al., 2002), but the growing awareness of the different
toxicological and physiological roles of the various Se speciesrebrospinal ﬂuid concentration of Se species: analysis removing observations with
Cases diagnosed  50 years (28 cases, 28 controls)
ses/#controls RR (95% CI) P-value #Cases/#controls
36 8.2 (1.5–46.2) .02 26/26
38 3.8 (0.4–39.6) .26 27/27
37 1.1 (1.0–1.2) .12 26/26
38 1.0 (0.9–1.2) .91 28/28
37 2.2 (1.0–4.7) .04 27/27
37 0.1 (0.01–0.8) .03 27/27
36 2.9 (1.0–8.4) .06 26/26
36 4.1 (0.8–21.3) .09 26/26
36 0.2 (0.03–0.95) .04 26/26
36 0.1 (0.02–0.96) .05 26/26
37 0.3 (0.1–1.1) .08 27/27
 albumin bound-Se and 1 mg/L for all other compounds.
nce of extreme outliers in the distributions of some Se species, observations with
 sample sizes for some analyses.
Table 3
Relative risks (RR) of amyotrophic lateral sclerosis associated with 1 mg/La increase in cerebrospinal ﬂuid concentration of Se species: analysis using winsorized variables.b
Se species All subjects (38 cases, 38 controls) Cases diagnosed 50 years (28 cases, 28 controls)
RR (95% CI) P-value #Cases/#controls RR (95% CI) P-value #Cases/#controls
Selenite 1.9 (0.8–4.6) .13 38/38 3.9 (1.1–13.0) .03 28/28
Selenate 0.9 (0.2–4.4) .88 38/38 1.9 (0.3–13.6) .54 28/28
Thioredoxin reductase-bound Se 1.0 (0.9–1.0) .37 38/38 1.0 (0.9–1.1) .65 28/28
Glutathione peroxidase-bound Se 1.0 (0.9–1.1) .73 38/38 1.0 (0.9–1.2) .58 28/28
Human serum albumin-bound Se 1.5 (0.9–2.4) .11 38/38 1.9 (1.0–3.6) .05 28/28
Selenoprotein P-bound Se 0.3 (0.08–0.8) .02 38/38 0.2 (0.06–0.9) .03 28/28
Total inorganic Se
Crude 1.4 (0.7–2.9) .30 38/38 3.2 (1.1–9.4) .04 28/28
Adjusted for organic Se 1.7 (0.8–3.9) .18 38/38 4.6 (1.1–20.2) .04 28/28
Total organic Se
Crude 0.4 (0.2–0.9) .03 38/38 0.4 (0.2–1.1) .07 28/28
Adjusted for inorganic Se 0.4 (0.2–0.9) .03 38/38 0.3 (0.1–1.0) .05 28/28
Total Se 0.5 (0.2–1.0) .05 38/38 0.5 (0.2–1.1) .09 28/28
a Unit increase is 0.1 mg/L for selenate, selenite, total inorganic Se and human serum albumin bound-Se and 1 mg/L for all other compounds.
b Results obtained from conditional logistic regression models. To reduce the inﬂuence of extreme outliers in the distributions of some Se species, Se variables were
winsorized by setting values above the 95th percentile to the 95th percentile.
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tions, we assessed whether speciﬁc Se compounds and particularly
the inorganic species represented a risk factor for ALS, prompted by
suggestive ﬁndings of epidemiologic studies (Kilness and Hoch-
berg, 1977; Vinceti et al., 1996, 2010b) and animal and laboratory
investigations (Vinceti et al., 2009; Maraldi et al., 2011; Estevez
et al., 2012). To the best of our knowledge, the present study is the
ﬁrst on Se speciation in ALS and more generally in human diseases,
among the large number of epidemiologic studies on health effects
of Se (Vinceti et al., 2009; Dennert et al., 2011). Our results indicate
the importance of Se speciation, despite the analytical complexity
and cost (Borella et al., 1996; Vinceti et al., 2009; Valdiglesias et al.,
2010; Nogueira and Rocha, 2011); RR estimates for total Se were
opposite to those for selenite or total inorganic Se, conﬁrming
recent results on total CSF Se from Norwegian ALS patients (Roos
et al., 2013), and thus an analysis based on total Se would have led
to opposite conclusions. This indicates that ﬁndings may be
seriously misleading if assessment is based on overall Se content of
body tissues and not speciﬁc Se species, highlighting the need to
focus on Se homeostasis, speciation and metabolism when
investigation the relation between this metalloid and CNS diseases
(Vinceti et al., 2012a; Steinbrenner and Sies, in press).
Use of CSF, a nervous system indicator of growing interest in
ALS (Sussmuth et al., 2008; Gladman et al., 2012; Mendonca et al.,
2012; Tarasiuk et al., 2012; von Neuhoff et al., 2012; Wilson et al.,
2013; Winer et al., 2013), as a biomarker of exposure rather than
peripheral indicators such as blood or toenails is an additional
strength of the present study. In our recent study on the relation
among CSF and other indicators in neurologically healthy subjects
(Solovyev et al., 2013), positive associations between CSF and
blood levels were found only for Se-GPx, Se-TrxR and Se-HSA,
while there was little or no correlation between CSF and blood
levels for other organic forms such as SePP, for selenite and
selenate (correlation coefﬁcients 0.03 and 0.23, respectively,
unpublished data by N.S. and B.M.), and total Se. Similarly, SePP in
the brain has been found to be independent of plasma circulating
levels (Scharpf et al., 2007). These ﬁndings indicate the inadequacy
of studies of inorganic Se not based on biomarkers of exposure
directly associated with target tissues. However, CSF is very rarely
used as a biomarker in epidemiologic studies, since it can be
collected only following speciﬁc medical indications, making it
infeasible to use not only in population-based but also in most
hospital-based investigations.
Previous studies on CNS Se content in ALS patients, which have
generally shown higher overall Se levels in brain and spinal cordcompared with controls (Mitchell et al., 1991; Moriwaka et al.,
1993; Ince et al., 1994; Markesbery et al., 1995) and highly variable
GPx activity (Przedborski et al., 1996), were conducted in deceased
subjects, and may therefore have suffered from the potential
inadequacy of post-mortem tissues in reﬂecting antecedent Se
content and enzyme activities. These studies were also limited by
small sample size and potential selection bias.
Our results indicate major abnormalities of Se compounds in
ALS, and support the hypothesis that inorganic Se and speciﬁcally
selenite may play a key role in the neurodegenerative process
characterizing ALS, in line with epidemiologic evidence implicat-
ing overexposure to environmental Se (Kilness and Hochberg,
1977) and to drinking water with high content of inorganic Se as
selenate (Vinceti et al., 1996, 2010b). Evidence supporting
biological plausibility of a relation between Se species, and
selenite in particular, and ALS has been provided from observations
in swine indicating that a few organic and particularly inorganic Se
species selectively kill motor neurons (Raber et al., 2010; Vinceti
et al., 2012a), a nematode model in which selenite speciﬁcally
affected motor function (Estevez et al., 2012) and recent in vitro
observations (Maraldi et al., 2011). Inorganic Se forms and selenite
in particular are well recognized in laboratory studies to be
considerably more toxic than organic species (Benko et al., 2012;
Peyroche et al., 2012; Vinceti et al., 2013), particularly for
neurotoxic effects (Ammar and Couri, 1981; Tsunoda et al.,
2000), even though they are retained in humans (Thomson
et al., 1993) and animals (Vinceti et al., 2009) at a considerably
lower rate than organic compounds. Selenite, and other Se species
(Zheng et al., 2012), can induce oxidative stress and mitochondrial
damage (Belyaeva and Saris, 2011; Ma et al., 2011), and both free
radical damage and mitochondrial abnormalities have been
implicated in ALS etiopathogenesis (Rossi et al., 2012). Selenite
in vitro has also been shown to induce other biochemical
alterations suggested to occur in ALS, such as copper/zinc
superoxide-dismutase (SOD1) translocation into mitochondria
and increased levels of reactive oxygen species and of inducible
nitric oxide synthase, with enhanced susceptibility to Se toxicity
by nervous cells compared with other cell types (Maraldi et al.,
2011). Low-dose Se exposure in humans may also induce DNA
damage (Karunasinghe et al., 2012) and P38-P53 activation (Chen
et al., 2010) as conﬁrmed by laboratory studies using selenite
(Rudolf et al., 2008), and these mechanisms are among those
suggested as involved in ALS etiopathogenesis (Kim and Choi,
2010; Coppede, 2011; Hanada et al., 2013). Finally, several studies
have suggested an inhibitory effect of selenite on inﬂammatory
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inﬂuence the relative distribution of selenium among body tissues
(Maehira et al., 2002), and inﬂammation has been recently
suggested to play a potential role in ALS etiology and pathogenesis
(Evans et al., 2013). Therefore, the possibility of a link between
altered Se compounds content in CNS and neuroinﬂammation in
ALS etiology merits further consideration.
In the previous epidemiologic study on consumers of drinking
water with high Se content in the Reggio Emilia area (Vinceti et al.,
1996), excess ALS risk was associated to high levels of Se as
selenate, the usual form of the metalloid in underground waters
(Vinceti et al., 2010b), while in the present study the increased
concentrations were found only for selenite. However, toxicity of
these two inorganic Se species, whose dietary intake is usually very
low, is comparable in some studies though not in all, with general
higher toxicity for selenite (Spyrou et al., 1996; Weiller et al., 2004;
Lunoe et al., 2011; Maraldi et al., 2011; Alturkmani et al., 2012;
Benko et al., 2012; Tsai et al., 2013). Moreover, a conversion
between these two inorganic Se forms, i.e. from the hexavalent
species (selenate) to the tetravalent one (selenite), has been shown
to occur as a chemical or a biological process (Hageman et al.,
2013) and it might also occur in the human (Gammelgaard et al.,
2012), though limited information on this issue is available.
The levels of selenite found in our study of CSF from ALS
patients were close to those (0.316 mg/L) found in an in vitro study
to induce apoptosis in cultured mouse cortical neurons (Xiao et al.,
2006). Toxic effects of selenite appear to be highly dependent on
cell type (Maraldi et al., 2011) and possibly, in nervous cells, on the
brain region involved (Zia and Islam, 2000). An additional
mechanism suggested to link excess Se to ALS risk is non-speciﬁc
incorporation of Se into proteins (Bell, 2009).
The cause of the elevated CSF selenite content detected in our
ALS patients may be attributable to several causes, such as excess
exposure to the compound from environmental sources, abnormal
and enhanced localization of this compound in the CNS, and
variations in response and repair pathways to selenite-induced
DNA damage (Manikova et al., 2012) or alteration of its
accumulation, detoxiﬁcation or toxicity (Sun et al., 2013), with
the possible involvement of genetic factors. About the latter, an
interplay between excess selenite exposure and genetics might
occur in sporadic ALS according to the ‘low-penetrance suscepti-
bility model,’ which hypothesizes some involvement of genetic as
well as environmental factors even in the non-familial form of the
disease (Sabatelli et al., 2013). Unfortunately, we did not have
available in our patients peripheral indicators of Se exposure such
as levels of blood or toenails Se species, which might have helped,
despite the limited ability of these biomarkers in reﬂecting
exposure to inorganic Se compared with organic (Vinceti et al.,
2001, 2009), to assess the possible environmental origin of the
excess CNS selenite content we detected. Ascertainment of
historical residence of study patients through the Revenue Agency
of the Ministry of Finance, which maintains records of historical
residence nationwide and could be accessed for research purposes
by one of us (Vinceti et al., 2012c), allowed us to rule out that any of
the study subjects had resided in Reggio Emilia area where
drinking water with high selenite content was distributed in the
1970s and 1980s (Vinceti et al., 2010a). However, we did not have
available any speciﬁc information about personal sources of
drinking water consumption and other potential environmental or
occupational exposures of study subjects to Se species.
Our observation of an inverse association between ALS risk and
levels of organic Se compounds and particularly SePP, with the
exception of Se-HSA, may imply a deﬁciency in antioxidant
response to free radical damage (Mandrioli et al., 2006) or more
generally a higher risk of neurodegeneration due to a deﬁciency of
proteins such as the antioxidant enzyme GPx (Wirth et al., 2010)and of SePP (Caito et al., 2011), which is considered a major source
of Se for Se-dependent enzyme synthesis and also has antioxidant
properties itself (Scharpf et al., 2007; Meplan et al., 2009). Reasons
for decreased organic Se levels in CSF of our ALS patients are
unclear, since they cannot be ascribed to a low Se supply, due to the
higher amount of inorganic Se available. Two possibly interrelated
hypotheses may be advanced: the role of unknown genetic or non-
genetic factors in reducing the antioxidant response, or the ability
of pro-oxidant Se species, including selenite, to reduce expression
of Se containing enzymes (Tallandini et al., 1996; Branco et al.,
2012; Medeiros et al., 2012), possibly through the induction of
oxidative stress (Suryo Rahmanto et al., 2012). On the other hand,
in other investigations selenite has been shown to increase brain
GPx activity as well as lipid peroxidation (Glaser et al., 2010), the
latter effect being possibly the cause of the former, and in human
and in vitro studies it appears to increase SePP levels (Meplan et al.,
2009; Hoeﬁg et al., 2011).
Recent animal and human studies investigating the relation of
SePP with neurological or other diseases have yielded sharply
different results (Bellinger et al., 2008, 2012; Yang et al., 2011;
Raman et al., 2012; Takata et al., 2012), not unexpectedly in
selenium research, making it difﬁcult to assess the biological
signiﬁcance of our ﬁndings. The hypothetical role of SePP in CNS
diseases is intriguing and controversial, ranging from beneﬁcial as
suggested by animal studies (Raman et al., 2012) to potentially
deleterious in human neurodegenerative diseases (Bellinger et al.,
2008, 2012). Scharpf et al. investigated the distribution of SePP in
the human CNS: they found very uneven localization, with high
SePP immunoreactivity in spinal, cranial and particularly pyrami-
dal motor neurons, and detected evidence supporting a crucial role
of SePP expression and activity in human brain (Scharpf et al.,
2007).
We observed an unexpected positive association between Se-
HSA and ALS risk. The exact nature of Se-HSA is unclear, but
available evidence suggests that it is mostly composed of organic
Se (Xu et al., 2008), though the occurrence of inorganic forms
cannot be ruled out (Haratake et al., 2008). Despite the lack of
information about the biological properties of this species of the
metalloid, we consider this ﬁnding worth further investigation in
future human studies on the role of Se in neurodegeneration. Se-
HSA might act as long-term storage of the metalloid for further
selenoprotein synthesis, thus suggesting the possibility that the
decreased SePP levels found in cases could be a consequence, on a
hypothetical basis, of a decreased Se re-mobilization and
availability from Se-HSA. Excess Se exposure in Chinese individuals
has been associated with preferential localization of Se in the Se-
HSA fraction, while in Se-deﬁcient or adequate subjects the
greatest Se amount was in the SePP fraction (Gu et al., 1998).
We found a stronger positive association between CSF selenite
and ALS risk among older subjects. A possible reason for enhanced
risk with older age may be the decreased role of genetic factors
supposed to be more important in triggering earlier onset disease
(Chio et al., 2012), indicating a greater role of environmental
variables in older subjects.
We must recognize limitations of the present study, including
the possibility that the disease process inﬂuenced the content of Se
species in CSF, and possibly in different ways for different
compounds. The possibility of reverse causality is inherent in
studies conducted with biomarkers in patients suffering from
disease; however, in the present study CSF sampling was
conducted at a very early stage of the disease, i.e. during the
clinical process leading to the its ﬁrst diagnosis, thus decreasing
the risk of disease-induced alterations in metabolism or intake.
Furthermore, the extent to which inorganic Se species, which are
not synthesized by the organism but rather absorbed, may reﬂect
long-term environmental overexposure is unknown, due to a lack
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areas. We selected as control subjects neurological patients whose
diagnosis was benign or null after their diagnostic process;
however, we cannot entirely rule out selection bias in the referent
population, possibly mediated by some risk factors affecting their
conditions that are correlated with differential exposure to Se
species. However, there is no a priori plausibility to such a
hypothesis, and our sensitivity analyses were unable to identify
trends supporting this possibility. Selection bias is unlikely to have
occurred in the ALS patient group, as they were selected among a
consecutive patient series admitted to the same hospital as control
patients and from the same underlying population, which was
furthermore quite homogeneous as to genetic and environmental
lifestyle factors. ALS patients undergoing lumbar puncture for CSF
sampling during the diagnostic process were more likely to be
younger and characterized by pyramidal signs than ALS cases not
undergoing this procedure who were therefore not included in the
present study; however, there is no reason to suspect an
association between these clinical features and alterations in
single Se species, and excess CSF selenite content was conﬁrmed
(and even enhanced) in our older study group. Finally, study size
was not large enough to yield statistically precise risk estimates, as
reﬂected by wide conﬁdence intervals surrounding the RRs, and
the data included outliers, which we attempted to deal with by
using multiple approaches to the analysis.
In conclusion, our results indicate a direct relation between ALS
risk and the concentration of selenite in CSF of newly diagnosed
ALS patients, as well an inverse association with the organic Se
form SePP which might be a related phenomenon, supporting the
hypothesis that overexposure to selenite may be an etiological risk
factor in the disease. Selenite may trigger neurodegenerative
effects through its powerful toxicity, which appears to be unique
among toxic chemicals, being highly speciﬁc toward motor
neurons in some animal studies.
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